Impact BioMedical, Inc. (IBO) - Total Assets
Based on the latest financial reports, Impact BioMedical, Inc. (IBO) holds total assets worth $18.21 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See IBO total equity for net asset value and shareholders' equity analysis.
Impact BioMedical, Inc. - Total Assets Trend (2016–2024)
This chart illustrates how Impact BioMedical, Inc.'s total assets have evolved over time, based on quarterly financial data.
Impact BioMedical, Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
Impact BioMedical, Inc.'s total assets of $18.21 Million consist of 12.1% current assets and 87.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $2.00 Million | 9.9% |
| Accounts Receivable | $184.00K | 0.9% |
| Inventory | $-265.00 | 0.0% |
| Property, Plant & Equipment | $17.00K | 0.1% |
| Intangible Assets | $17.81 Million | 87.8% |
| Goodwill | $17.79 Million | 87.7% |
Asset Composition Trend (2016–2024)
This chart illustrates how Impact BioMedical, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Impact BioMedical, Inc. market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Impact BioMedical, Inc.'s current assets represent 12.1% of total assets in 2024, a decrease from 100.0% in 2016.
- Cash Position: Cash and equivalents constituted 9.9% of total assets in 2024, down from 95.6% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 174.0% of total assets, an increase from 0.0% in 2016.
- Asset Diversification: The largest asset category is intangible assets at 87.8% of total assets.
Impact BioMedical, Inc. Competitors by Total Assets
Key competitors of Impact BioMedical, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Merus BV
NASDAQ:MRUS
|
USA | $771.99 Million |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥7.26 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068
|
China | CN¥3.21 Billion |
|
Savara Inc
NASDAQ:SVRA
|
USA | $140.92 Million |
|
Wuhan Hvsen Biotechnology Co Ltd
SHE:300871
|
China | CN¥2.96 Billion |
|
Wecome Pharmaceutical Co Ltd
SHE:300878
|
China | CN¥1.49 Billion |
|
Shanghai Shen Lian Biomedical Corp
SHG:688098
|
China | CN¥1.56 Billion |
Impact BioMedical, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.04 | 2.79 | 3.98 |
| Quick Ratio | 0.02 | 2.79 | 3.98 |
| Cash Ratio | 0.00 | 2.34 | 0.00 |
| Working Capital | $-22.88 Million | $2.04 Million | $53.67K |
Impact BioMedical, Inc. - Advanced Valuation Insights
This section examines the relationship between Impact BioMedical, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.24 |
| Latest Market Cap to Assets Ratio | 2.24 |
| Asset Growth Rate (YoY) | -54.5% |
| Total Assets | $20.29 Million |
| Market Capitalization | $45.54 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Impact BioMedical, Inc.'s assets at a significant premium (2.24x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Impact BioMedical, Inc.'s assets decreased by 54.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Impact BioMedical, Inc. (2016–2024)
The table below shows the annual total assets of Impact BioMedical, Inc. from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $20.29 Million | -54.54% |
| 2023-12-31 | $44.63 Million | -4.01% |
| 2022-12-31 | $46.50 Million | +1064.82% |
| 2021-12-31 | $3.99 Million | +5387.43% |
| 2020-12-31 | $72.74K | -37.62% |
| 2019-12-31 | $116.61K | -46.31% |
| 2018-12-31 | $217.21K | -32.26% |
| 2017-12-31 | $320.66K | -20.94% |
| 2016-12-31 | $405.60K | -- |
About Impact BioMedical, Inc.
Impact BioMedical Inc. discovers, develops, and commercializes products and technologies to address unmet needs in human healthcare and wellness for specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare, and wellness products in the United States. The company provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with application … Read more